Journal Mobile Options
Table of Contents
Vol. 10, No. 3, 1999
Issue release date: May–June 1999
Dement Geriatr Cogn Disord 1999;10:237–244

The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

Burns A. · Rossor M. · Hecker J. · Gauthier S. · Petit H. · Möller H.-J. · Rogers S.L. · Friedhoff L.T.
aWithington Hospital, Manchester, UK; bThe Institute of Neurology, London, UK; cRepatriation General Hospital, Daw Park, Australia; dMcGill Center for Studies in Aging, Quebec, Canada; eUniversity of Lille, Lille, France; fLudwig-Maximilians-Universität, München, Germany; and gEisai Inc., Teaneck, N.J., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer’s disease (AD). The current trial was undertaken to investigate further the efficacy and safety of donepezil, in a multinational setting, in patients with mild to moderately severe AD. This 30-week, placebo-controlled, parallel-group study consisted of a 24-week, double-blind treatment phase followed by a 6-week, single-blind, placebo washout. Eight hundred and eighteen patients with mild to moderately severe AD were randomly allocated to treatment with single, daily doses of 5 or 10 mg donepezil, or placebo. The two primary efficacy measures were: a cognitive performance test, the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and a global evaluation, the Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC plus). Secondary outcome measures included the Sum of the Boxes of the Clinical Dementia Rating Scale (CDR-SB), a modified Interview for Deterioration in Daily living activities in Dementia (IDDD) and a patientrated quality of life assessment. Statistically significant improvements in cognitive and global function were observed, as evaluated by ADAS-cog and CIBIC plus, respectively, in both the 5 and 10 mg/day donepezil groups, compared with placebo. Treatment-associated changes were also observed in functional skills, as shown by improved scores on the CDR-SB and the complex-tasks component of the IDDD. A dose–response effect was evident, with the 10 mg/day donepezil group demonstrating greater benefits in all outcome measures than the 5 mg/day group. Donepezil was well tolerated by this patient population and did not produce any clinically significant laboratory test abnormalities. The results of this study confirm that donepezil is effective and well tolerated in treating the symptoms of mild to moderately severe AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR, Dartigues JF, Engedal K, Hagnell O, Heeren TJ: Frequency and distribution of Alzheimer’s disease in Europe: A collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 1991;30:381–390.
  2. Wenk GL: The nucleus basalis magnocellularis cholinergic system: One hundred years of progress. Neurobiol Learn Mem 1997;67:85–95.
  3. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K: Inhibitory action of E2020, a novel acetylcholinesterase inhibitor, on cholinesterase: Comparison with other inhibitors; in Nagatsu T, Yoshida M, Fisher A (eds): Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases. New York, Plenum Press, 1990, pp 409–413.
  4. Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 1998;46(suppl 1):1–6.
  5. Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998;46(suppl 1):7–12.
  6. Tiseo PJ, Rogers SL, Friedhoff LT: Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998;46(suppl 1):13–18.
  7. Rogers SL, Yamanishi Y, Yamatsu K: E2020: The pharmacology of a piperidine cholinesterase inhibitor; in Becker R, Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston, Birkhäuser, 1991, pp 314–320.
  8. Mihara M, Ohnishi A, Tomono Y, Hasegawa J, Shimamura Y, Yamazaki Y, Morishita N: Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 1993;31:223–229.
  9. Rogers SL, Friedhoff LT, and the Donepezil Study Group: The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293–303.
  10. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, and the Donepezil Study Group: Donepezil improves cognition and global function in Alzheimer’s disease: A 15-week, double-blind, placebo-controlled study. Arch Int Med 1998;158:1021–1031.
  11. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, and the Donepezil Study Group: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.
  12. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67–75.

    External Resources

  13. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and cimetidine: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(suppl 1):25–29.
  14. Tiseo PJ, Perdomo CA, Friedhoff LT: Concurrent administration of donepezil HCl and ketoconazole: Assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(suppl 1):30–34.
  15. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 3, revised. Washington, American Psychiatric Association, 1987.
  16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force in Alzheimer’s disease. Neurology 1984;34:939–944.
  17. Folstein MF, Folstein SE, McHugh PR: ‘Mini-Mental State’. A practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975;12:189–198.
  18. Hughes CD, Berg L, Danziger L, Coben LA, Martin RL: A new rating scale for the staging of dementia. Br J Psychiatry 1982;140:566–572.
  19. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–1364.
  20. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH, the Alzheimer’s Disease Cooperative Study: Validity and reliability of the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S22–S32.
  21. Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G: Mild senile dementia of the Alzheimer type: 4 evaluations of intervention. Ann Neurol 1992;31:242–249.
  22. Teunisse S, Derix M, van Crevel H: Assessing the severity of dementia, patient and caregiver. Arch Neurol 1991;48:274–277.
  23. Blau TH: Quality of life, social indicators and criteria of change. Prof Psychol 1977;8:464–473.
  24. Leber P: US Food and Drug Administration, Center for Drug Evaluation and Research, Division of Neuropharmacological Drug Products. Form and Contents of NDA Reviews: Strategies for the Efficacy Analysis. November 5, 1985.
  25. Cochran WG: Some methods for strengthening the common χ2 tests. Biometrics 1954;10:417–451.
  26. Bross IDJ: How to use RIDIT analysis. Biometrics 1958;14:18–38.
  27. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Epidemiology and Biostatistics: COSTART: Coding symbols for thesaurus of adverse reaction terms, ed 4. Pub PB93-209138, 1993.
  28. Rogers SL, Friedhoff LT: Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer’s disease. Eur Neuropsychopharmacol 1997;7(S2):S251.
  29. US Package Insert: Aricept® (donepezil hydrochloride tablets), September 1998.
  30. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33–S39.
  31. Doraiswamy PM: Current cholinergic therapy for symptoms of Alzheimer’s Disease. Primary Psychiatry 1996;3(11):56–68.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50